Today’s article examines a particular, well-established anomaly of the stock market – the short-term reversal effect – and how active traders can use a simple rotational strategy to take advantage of this anomaly and significantly outperform the market. For more on the short-term reversal anomaly, the strategy to benefit directly from it – and whether traders can still use this strategy in these unusual times – CLICK HERE.
Today’s article highlights two cheap healthcare stocks that, while having suffered so far this year, have growth drivers at hand that should set them up for rebounds going forward: “The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible drug approvals in the coming months. And the second great deal is a diagnostics player with a huge opportunity in cancer screening.” For more, CLICK HERE.
With all the attention the top-performing health care sector, and biopharmaceutical stocks in particular, are receiving, which biotech stocks are worth a look ahead of their first-quarter earnings reports? Analysts at Goldman Sachs have identified four that they are bullish on, and today’s article notes that “While their shares only suited for aggressive growth accounts with a high-risk profile, none of these companies is a proverbial one-trick pony. In addition, they all are potential takeover candidates.” For more, CLICK HERE.
Noting that we’re “beginning to see selectivity creep back into the marketplace following a period of indiscriminate buying”, the author of today’s article proceeds to identify the best sectors right now across large-cap, mid-cap and small-cap stocks, as well as a slew of “top scoring stocks” from those select sectors that may be the best buys for stock pickers right now. For more, CLICK HERE.
After the coronavirus-driven market selloff – and subsequent snap-back – the pivotal question right now, suggests the author of today’s article, is whether this is now a stock-pickers’ market, or whether macro matters most and all stocks are essentially equal. And if it is a stock-pickers’ market, what are some stocks worth picking? For how a panel of stock-pickers are answering these questions – and more – CLICK HERE.
When it comes to the three clinical-stage biotech stocks highlighted in today’s article, the author declares that, while they are all “relatively small at the moment…they have potential blockbuster drugs in development that could send their stock prices screaming higher.” For these three biotech stocks whose ultra risk could lead to ultra riches with clinical trial success, CLICK HERE.
“While the overall market flirts with a bear, OTC stocks have been on fire,” observes the author of today’s article. And while he acknowledges that OTC stocks strike fear in many people, he reveals that many of his trades recently have been OTC stocks – and he outlines how to play it safe while playing with OTC stocks. For “the 5 Ps of OTC stocks” in the age of coronavirus, CLICK HERE.
“With some investors now looking to take on a bit more risk, they are turning to the ultimate risk/reward plays: biotech stocks,” notes the author of today’s article. One of the few major catalysts for biotech stocks is regulatory approval – and the author highlights “three compelling biotech stocks with upcoming Prescription Drug User Fee Act (PDUFA) dates, the deadline by which the FDA must decide to approve or reject a new application.” For these three biotech stocks with “Strong Buy” analyst ratings and significant upside potential – including one firm at the forefront of women’s reproductive health – CLICK HERE.
If you want to earn just “average” gains in the post-coronavirus economy, invest in broad index funds. But if you want better-than-average returns, stock and non-broad-based ETF picking will be the way to go, argues the author of today’s article. Just what are the many major shifts – from privacy rights to education to biotechnology – that the economy will undergo as a result of the coronavirus pandemic, and which stocks and ETFs will benefit? CLICK HERE.
An estimated 70 million Americans suffer from insomnia – and that number is undoubtedly climbing as the country deals with the stress and anxiety associated with the COVID-19 pandemic. While many for whom sleep proves to be elusive turn to prescription medications and over-the-counter sleep aids, there’s evidence that adults are increasingly turning to cannabis to help promote sleep – and today’s article highlights two cannabis companies that are honing in on this potentially lucrative market. For more on this new cannabis opportunity, CLICK HERE.